← Back to Search

Anti-obesity Agent

Part 1 - Single Ascending Dose for Obesity

Phase 1
Recruiting
Research Sponsored by NeuroBo Pharmaceuticals Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Females of non-reproductive potential: Postmenopausal or with history of hysterectomy or bilateral oophorectomy
Males and females >18 to <65 years of age, diagnosed with obesity or signs/symptoms consistent with obesity
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from date of randomization (baseline) until the discontinuation or completion, whichever came first, assessed up to 26 days for part 1 and 47 days for part 2.
Awards & highlights

Study Summary

This trial is testing a new drug called DA-1726 in people who are obese but otherwise healthy. The main goal is to see if the drug is safe and well-tolerated when given in

Who is the study for?
This trial is for adults aged 18-65 with obesity (BMI >30 to <45), who are otherwise healthy. Women must be non-reproductive, and men should use birth control during the study. Participants can't have had significant weight changes or started new diets/exercise in the last 3 months, and they must not use tobacco or have certain medical conditions.Check my eligibility
What is being tested?
The trial tests DA-1726 against a placebo in people with obesity. It aims to check how safe it is and how well participants tolerate different doses over time. The study involves single and multiple dose administrations while maintaining a standard diet.See study design
What are the potential side effects?
Since this is a first-in-human study, specific side effects of DA-1726 aren't listed but may include typical drug reactions like digestive issues, allergic responses, fatigue, or other unexpected symptoms as observed during the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a woman who cannot have children because I am postmenopausal or have had surgery.
Select...
I am between 18 and 65 years old and have been diagnosed with obesity.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from date of randomization (baseline) until the discontinuation or completion, whichever came first, assessed up to 26 days for part 1 and 47 days for part 2.
This trial's timeline: 3 weeks for screening, Varies for treatment, and from date of randomization (baseline) until the discontinuation or completion, whichever came first, assessed up to 26 days for part 1 and 47 days for part 2. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Secondary outcome measures
Immunogenicity
Pharmacokinetic

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Part 1 - Single Ascending DoseActive Control2 Interventions
Single doses of DA-1726 in adult participants (aged 18 to 65 years) with obesity (BMI ≥30 - 45 kg/m2). DA-1726 will be administered via subcutaneous (SC) injection within the clinic setting.
Group II: Part 2 - Multiple Ascending DosePlacebo Group2 Interventions
Multiple doses of DA-1726 in adult participants (aged 18 to 65 years) with obesity (BMI ≥30 - 45 kg/m2). DA-1726 will be administered via subcutaneous (SC) injection within the clinic setting.

Find a Location

Who is running the clinical trial?

NeuroBo Pharmaceuticals Inc.Lead Sponsor
14 Previous Clinical Trials
1,252 Total Patients Enrolled
~54 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top